

# PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

(Under the Department of Pharmaceuticals, Govt. of India)

B-500, B-Tower, 5<sup>th</sup> Floor, Nauroji Nagar, World Trade Center, New Delhi-110029

## Amendment No. 2

No: PMBI/DRUG/RC-222/2025/02

Dated: 26/05/2025

**Subject: e-Tender No. PMBI/DRUG/RC-222/2025 dated 30/04/2025 for supply of Drugs to Pharmaceuticals & Medical Devices Bureau of India (PMBI).**

Pharmaceuticals & Medical Devices Bureau of India (PMBI) has invited e-Bids from the interested parties for Supply of Drugs for the year '2025-2027', vide Notice Inviting e-Tender No.- PMBI/DRUG/RC-222/2025 dated 30/04/2025. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on Central Public Procurement Portal; [www.eprocure.gov.in](http://www.eprocure.gov.in) as well as PMBI Website; [www.janaushadhi.gov.in](http://www.janaushadhi.gov.in).

The following amendment in Tender Document is hereby authorized through Part-A, Part-B and Part-C: -

### • Part-A

Sr. No.	Tender Clause/ Reference	Queries/ Suggestions	Clarification/ Amendment
1	Clause 3: I: ELIGIBILITY CRITERIA (Technical Bid- Cover "A"): at page 9 of the tender document.	Some of the intending bidders have requested to relax/ reduce the requirement of annual average turnover for three consecutive years of the last four financial years from Rs. 50 Crores (Fifty crores).	<b><u>Tender condition prevails.</u></b>
2	Clause 3: U: ELIGIBILITY CRITERIA (Technical Bid- Cover "A"): At page 10 of tender document.	Bidder has requested to relax the submission of Batch Manufacturing Record (BMR) with Technical Bid (Cover-A), or to allow them to submit the aforementioned documents for the awarded drug codes.	<b><u>Tender condition prevails.</u></b>
3	Clause 3: G: ELIGIBILITY CRITERIA (Technical Bid- Cover "A"): At page 9 of tender document	Bidder has requested to remove the requirement for submission of Certificate of Pharmaceutical Product (CoPP) for each quoted product issued by the Drug Licensing Authority/ Drugs Control Department as per tender clause 3.G, stating that 'CoPP is not a mandatory requirement for bidders holding valid WHO-GMP certificate.'	<b><u>Tender condition prevails.</u></b> However, bids may be submitted with duly acknowledged application for Certificate of Pharmaceutical Product (CoPP) against the quoted drugs issued by the concerned Drug Licensing Authority/ State Licensing Authority (SLA)/ Drugs Control Department, and a declaration on company letter-head along with the bid documents. The duly issued CoPP certificates shall be submitted immediately upon receipt.

4	Clause 3: D: (e): At page 9 of tender document.	Bidder has requested for relaxation in submission of Market Standing Certificate (MSC) & Certificate of Pharmaceutical Product (CoPP certificate) in case of New Drugs.	It is clarified that as per tender clause 3.D.(f) ' <i>In case of drug where patent has recently been released (in 2021-2024) submission of market Standing Certificate may be exempted. However, if the patent is expired before F.Y. 2021-22, bid of such drugs may be accepted with two-year Market Standing Certificate</i> '. and submission of CoPP certificate may be relaxed for the drugs where patent has been recently released.
5	Clause 19: Supply Conditions at page 21 of tender document	Bidder has requested for amendment and extension in the specified delivery schedule.	<b><u>Tender condition prevails.</u></b>

• **Part-B**

The following Amendment in detailed Specification/ packaging/ unit size is hereby authorized: -

Sl. No	Tender Clause/ Reference	Drug Code	Generic Name of the Drug	Detailed Specification	Unit Size	Bidders Query	Amendment
1	Annexure - XII Clause 18 (M)	10	Diclofenac Sodium Injection IP 25mg per ml	Each ml contains: Diclofenac Sodium IP 25mg	3ml Ampoule	Bidder has requested for amendment in the packaging size as 1's x 5 instead of 1's x 10	<b><u>Tender condition prevails.</u></b>
2	Annexure - XII Clause 18 (M)	31	Amikacin Injection IP 250 mg per 2 ml	Each ml contains: Amikacin sulphate IP equivalent to Amikacin 125 mg	2ml Vial	Bidder has requested for amendment in the packaging size as 2ml x 8 instead of 2ml x 10	<b><u>Tender condition prevails.</u></b>
3	Annexure - XII Clause 18 (M)	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Each film-coated sustained release tablet contains: Metformin Hydrochloride IP 1000mg	10's	Bidder has requested for amendment in the detailed specification as Each uncoated tablet contains: Metformin Hydrochloride IP 1000mg	<b><u>Tender condition prevails.</u></b>
4	Annexure - XII Clause 18 (M)	150	Pioglitazone 15mg and Metformin 500mg Sustained Release Tablets	Each uncoated bilayer tablet contains: Metformin Hydrochloride IP 500mg (As sustained release form) Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg	10's	Bidder has requested to accept the packaging type as Alu-Alu pack instead of Blister pack	<b><u>Tender condition prevails.</u></b>
5	Annexure - XII Clause 18 (M)	208	Ondansetron Injection IP 2mg per ml	Each ml contains: Ondansetron Hydrochloride IP eq. to Ondansetron 2 mg	2ml Ampoule	Bidder has requested for amendment in the packaging size as 2ml x 5 instead of 1's x 10	<b><u>Tender condition prevails.</u></b>

6	Annexure - XII Clause 18 (M)	209	Ondansetron Tablets IP 4 mg	Each film-coated tablet contains: Ondansetron Hydrochloride IP equivalent to Ondansetron 4mg	10's	Bidder has requested to accept the packaging type as Strip pack instead of Blister pack	<b><u>Tender condition prevails.</u></b>
7	Annexure - XII Clause 18 (M)	216	Ranitidine Injection IP 25 mg per ml	Each ml contains: Ranitidine Hydrochloride IP eq. to Ranitidine 25mg (1.12g of Ranitidine Hydrochloride is eq. to approximately 1g of Ranitidine)	2ml Ampoule	Bidder has requested for amendment in the packaging size as 2ml x 5 instead of 1's x 10	<b><u>Tender condition prevails.</u></b>
8	Annexure - XII Clause 18 (M)	267	Atorvastatin Tablets IP 20mg	Each Film-Coated tablet contains: Atorvastatin Calcium IP equivalent to Atorvastatin 20mg	10's	Bidder has requested to accept the packaging type as Strip pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
9	Annexure - XII Clause 18 (M)	287	Losartan Potassium and Hydrochlorothiazide 12.5mg Tablets IP	Each Film Coated tablet contains: Losartan Potassium IP 50mg Hydrochlorothiazide IP 12.5 mg	10's	Bidder has requested to accept the detailed specification as Uncoated tablet form instead of Film-coated tablet form and also, to accept the packaging type as Blister pack instead of Alu-Alu pack	Amendment in the packaging specification is hereby authorized as: <b>Blister</b>
10	Annexure - XII Clause 18 (M)	311	Disodium Hydrogen Citrate Syrup (Alkalyser) 1.4 gm per 5 ml	Each 5ml contains: Disodium Hydrogen Citrate 1.4gm	100 ml	Bidder has requested for amendment in the detailed specification as Each 5ml contains: Disodium Hydrogen Citrate 1.37gm	Amendment in the Generic Name is hereby authorized as: Disodium Hydrogen Citrate Syrup 1.4 gm per 5 ml
11	Annexure - XII Clause 18 (M)	344	Ciprofloxacin Eye Drops IP 0.3% w/v	Composition: Ciprofloxacin Hydrochloride IP eq. to Ciprofloxacin 0.3% w/v Benzalkonium Chloride Solution IP 0.025% W/V Purified water IP q.s.	5 ml	Bidder has requested for amendment in the unit size as 10ml instead of 5ml	Amendment in the unit size is hereby authorized as: <b>10 ml</b>
12	Annexure - XII Clause 18 (M)	372	Metformin Hydrochloride Prolonged-released Tablets IP 500 mg	Each film coated Prolonged Release tablet contains: Metformin Hydrochloride IP 500mg	10's	Bidder has requested for amendment in the detailed specification as Each uncoated tablet contains: Metformin Hydrochloride IP 500mg	<b><u>Tender condition prevails.</u></b>
13	Annexure - XII Clause 18 (M)	456	Atorvastatin Tablets IP 40 mg	Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg	10's	Bidder has requested to accept the packaging type as Strip pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>

14	Annexure - XII Clause 18 (M)	473	Pantoprazole 40mg (Enteric Coated) and Levosulpiride 75mg (Sustained Release) Capsules	Each hard gelatin capsule contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg (As enteric coated pellets) Levosulpiride 75mg (As Sustained release pellets)	10's	Bidder has requested for clarification of the packaging type.	The authorized packaging type of DC-473 is as follows  <b>Alu-Alu</b>
15	Annexure - XII Clause 18 (M)	492	Sulfasalazine Delayed Release Tablets 500mg	Each enteric-coated tablet contains: Sulfasalazine 500mg	10's	Bidder has requested for amendment in the detailed specification as Each gastro-resistant tablet contains: Sulfasalazine 500mg	<b><u>Tender condition prevails.</u></b>
16	Annexure - XII Clause 18 (M)	507	Carbimazole Tablets IP 5 mg	Each uncoated tablet contains: Carbimazole IP 5 mg	10's	Bidder has requested to accept the unit size and packaging size as 100's in bottle	<b><u>Tender condition prevails.</u></b>
17	Annexure - XII Clause 18 (M)	512	Aceclofenac 100mg, Paracetamol 325mg and Serratiopeptidase 15mg Tablets	Each film coated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coted form)	10's	Bidder has requested to accept the packaging type as Blister pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
18	Annexure - XII Clause 18 (M)	529	Levosambutamol 1.25mg and Ipratropium 500mcg Respules	Each 2.5ml respule contains: Ipratropium Bromide IP equivalent to Ipratropium Bromide (anhydrous) 500mcg Levosambutamol Tartrate equivalent to Levosambutamol 1.25mcg	2.5 ml	Bidder has requested to accept the unit size as 3 ml.	Amendment in the detailed specification and unit size are hereby authorized as: <b>Detailed specification:</b> Each 3ml respule contains: Ipratropium Bromide IP equivalent to Ipratropium Bromide (anhydrous) 500mcg Levosambutamol Tartrate equivalent to Levosambutamol 1.25mcg <b>Unit Size: 3 ml</b>
19	Annexure - XII Clause 18 (M)	791	Atenolol 25mg and Amlodipine 5mg Tablets IP	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Atenolol IP 25mg	14's	Bidder has requested to accept the packaging type as Blister pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>

20	Annexure - XII Clause 18 (M)	832	Chlorthalidone Tablets IP 12.5mg	Each uncoated tablet contains: Chlorthalidone IP 12.5mg	10's	Bidder has requested to accept the packaging type as Blister pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
21	Annexure - XII Clause 18 (M)	1246	Fluconazole Tablets IP 150 mg	Each uncoated tablet contains: Fluconazole IP 150mg	1's	Bidder has requested for amendment in the unit size as 6's instead of 1's	<b><u>Tender condition prevails.</u></b>
22	Annexure - XII Clause 18 (M)	1308	Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg Tablets IP	Each uncoated tablet contains: Ethinylestradiol IP 0.03mg Levonorgestrel IP 0.15 mg	21's	Bidder has requested to accept the detailed specification as film-coated tablet form instead of un-coated tablet form.	<b><u>Tender condition prevails.</u></b>
23	Annexure - XII Clause 18 (M)	1368	Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg Tablets	Each film coated tablet contains: Olmesartan Medoxomil 20 mg Hydrochlorothiazide IP 12.5 mg	10's	Bidder has requested to accept the packaging type as Alu-Alu pack instead of Strip pack	<b><u>Tender condition prevails.</u></b>
24	Annexure - XII Clause 18 (M)	1575	Clobetasol Propionate 0.05%w/w and Gentamicin 0.1%w/w Cream	Contains: Clobetasol Propionate 0.05% w/w Gentamicin 0.1% w/w	25g	Bidder has requested to amend the unit size as 30g instead of 20g.	<b><u>Tender condition prevails.</u></b>
25	Annexure - XII Clause 18 (M)	1607	Drotaverine Hydrochloride Tablets IP 80 mg	Each film coated tablet contains: Drotaverine Hydrochloride IP 80 mg	15's	Bidder has requested to amend and accept the unit size as 10's instead of 15's	<b><u>Tender condition prevails.</u></b>
26	Annexure - XII Clause 18 (M)	1645	Gliclazide 60mg (Modified Release) and Metformin 500mg (Extended Release) Tablets	Each uncoated bilayered tablet contains: Gliclazide 60mg (in modified release form) Metformin Hydrochloride 500mg (in extended-release form)	10's	Bidder has requested to accept the packaging type as Blister pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
27	Annexure - XII Clause 18 (M)	1670	Ivabradine Tablets 5mg	Each film-coated tablet contains: Ivabradine 5mg	15's	Bidder has requested to amend and accept the unit size as 10's instead of 15's	<b><u>Tender condition prevails.</u></b>
	Annexure - XII Clause 18 (M)	1671	Ivabradine Tablets 5mg	Each film-coated tablet contains: Ivabradine 5mg	15's	Bidder has requested to accept the unit size and packaging size as 15's in bottle	<b><u>Tender condition prevails.</u></b>
28	Annexure - XII Clause 18 (M)	1679	Lecithin Capsules 1000mg	Each soft gelatin capsule contains: Lecithin 1000 mg	10's	Bidder has requested to accept the packaging specification as Amber color blister instead of Transparent Blister	Amendment in the packaging specification is hereby authorized as <b>Amber color blister</b>



29	Annexure - XII Clause 18 (M)	1683	Levocetirizine Dihydrochloride Tablets IP 10mg	Each film coated tablets contains: Levocetirizine Dihydrochloride IP 10mg	15's	Bidder has requested for amendment in the packaging specification as PVC Blister instead of Alu-Alu.	Amendment in the packaging specification is hereby authorized as: <b>Blister</b>
30	Annexure - XII Clause 18 (M)	1733	Omeprazole 20mg and Domperidone 30mg (Sustained Release) Capsules	Each hard gelatin Capsule contains: Omeprazole 20 mg (as enteric coated pellets) Domperidone 30 mg (as sustained release pellets)	15's	Bidder has requested to amend and accept the unit size as 10's instead of 15's	<b><u>Tender condition prevails.</u></b>
31	Annexure - XII Clause 18 (M)	1753	Paracetamol 500 mg, Phenylephrine 10 mg and Chlorpheniramine 2 mg Tablet	Each Film-coated tablet contains: Paracetamol 500 mg Phenylephrine 10 mg Chlorpheniramine 2 mg	10's	Bidder has requested to accept the packaging type as Alu-Alu pack instead of Blister pack	<b><u>Tender condition prevails.</u></b>
32	Annexure - XII Clause 18 (M)	1774	Racecadotril Capsule IP 100 mg	Each Hard Gelatin capsule contains: Racecadotril 100 mg	15's	Bidder has requested to amend and accept the unit size as 10's instead of 15's	<b><u>Tender condition prevails.</u></b>
33	Annexure - XII Clause 18 (M)	1783	Rosuvastatin IP 20mg and Fenofibrate IP 160mg Tablets	Each film coated tablets contains: Rosuvastatin Calcium equivalent to Rosuvastatin IP 20mg Fenofibrate IP 160mg	10's	Bidder has requested to accept the packaging type as Alu-Alu pack instead of Strip pack	<b><u>Tender condition prevails.</u></b>
34	Annexure - XII Clause 18 (M)	1833	Ursodeoxycholic Acid Tablets IP 150mg	Each uncoated tablet contains: Ursodeoxycholic Acid IP 150mg	15's	Bidder has requested to amend and accept the unit size as 10's instead of 15's	<b><u>Tender condition prevails.</u></b>
35	Annexure - XII Clause 18 (M)	1982	Cefixime 100mg and Potassium Clavulanate Acid 62.5mg Tablets	Each Film coated tablet contains: Cefixime Trihydrate IP equivalent to Anhydrous Cefixime 100mg Potassium Clavulanate equivalent to Clavulanic Acid 62.5mg	10's	Bidder has requested to amend the detailed specification as uncoated dispersible tablet form instead of film-coated tablet form.	Amendment in the Generic Name is hereby authorized as: Cefixime 100mg and Potassium Clavulanate 62.5mg Tablets
36	Annexure - XII Clause 18 (M)	2137	Telmisartan 40mg, Cilnidipine 10mg and Chlorthalidone 12.5mg Tablets	Each film coated tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Chlorthalidone IP 12.5 mg	10's	Bidder has requested to accept the packaging type as Strip pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
37	Annexure - XII Clause 18 (M)	2327	Omega 3 Fatty Acid 500mg EPA 150mg DHA 100mg Bilberry Extract 50mg Lutein 20% & Zeaxanthin 4%-25mg Beta carotene	Each Soft gelatin capsule contains: Omega 3 Fatty Acid 500 mg EPA 150 mg DHA 100 mg Bilberry Extract 50 mg	30's Bottle	Bidder has requested for amendment in the packaging specification as Alu-PVC Blister instead of Bottle in monocarton.	<b><u>Tender condition prevails.</u></b>

			4.8mg Vitamin D3 10mcg Capsules	Lutein 20% & Zeaxanthin 4%- 25 mg Beta carotene 4.8 mg Vitamin D3 10 mcg			
38	Annexure - XII Clause 18 (M)	2328	Methylcobalamin 1500 mcg, Vitamin B6 (Pyridoxine) 5mg Benfotiamine 50 mg Alpha Lipoic Acid 200 mg Folic Acid 5 mg Biotin 5 mg Capsule	Each Soft gelatin capsule contains: Methylcobalamin 1500 mcg Vitamin B6 (Pyridoxine) 5 mg Benfotiamine 50 mg Alpha Lipoic Acid 200 mg Folic Acid 5 mg Biotin 5 mg	10's	Bidder has requested for amendment in the packaging specification as Alu-PVC Blister instead of Alu-Alu.	Amendment in the packaging specification is hereby authorized as:  <b>Blister</b>
39	Annexure - XII Clause 18 (M)	2370	Nebivolol 5mg and Cilnidipine 10mg Tablets	Each Film coated bi-layered tablet contains Nebivolol Hydrochloride IP equivalent To Nebivolol 5mg Cilnidipine IP 10 mg	10's	Bidder has requested to accept the detailed specification as film- coated tablet form instead of film- coated bi-layered tablet form.	<b><u>Tender condition prevails.</u></b>
40	Annexure - XII Clause 18 (M)	2371	Nebivolol 2.5mg and Cilnidipine 10mg Tablets	Each Film coated bi-layered tablet contains Nebivolol Hydrochloride IP equivalent To Nebivolol 2.5mg Cilnidipine IP 10 mg	10's	Bidder has requested to accept the detailed specification as film- coated tablet form instead of film- coated bi-layered form.	<b><u>Tender condition prevails.</u></b>
41	Annexure - XII Clause 18 (M)	2385	Apixaban Tablets 2.5mg	Each Film Coated tablet contains: Apixaban 2.5mg	10's	Bidder has requested to accept the packaging type as Blister pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
42	Annexure - XII Clause 18 (M)	2386	Apixaban Tablets 5mg	Each Film Coated tablet contains: Apixaban 5mg	10's	Bidder has requested to accept the packaging type as Blister pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
43	Annexure - XII Clause 18 (M)	2392	Azelnidipine 16 mg Tablets	Each Uncoated tablet contains: Azelnidipine IP 16 mg	10's	Bidder has requested to accept the packaging type as Alu-Alu pack instead of Blister pack	<b><u>Tender condition prevails.</u></b>
44	Annexure - XII Clause 18 (M)	2393	Telmisartan 40 mg and Azelnidipine 8 mg Tablets	Each Film coated bi-layered tablet contains: Telmisartan IP 40 mg Azelnidipine IP 8 mg	10's	Bidder has requested to accept the packaging type as Alu-Alu pack instead of Composite Blister pack	Amendment in the packaging specification is hereby authorized as: Alu-Alu
45	Annexure - XII Clause 18 (M)	2394	Azelnidipine 8 mg Tablets	Each Uncoated tablet contains: Azelnidipine IP 8 mg	10's	Bidder has requested to accept the packaging type as Alu-Alu pack instead of Blister pack	<b><u>Tender condition prevails.</u></b>
46	Annexure - XII Clause 18 (M)	2449	Oral Rehydration Salts IP (WHO Formula) Orange Flavour Sachet, 21g	Each Sachet contains: Sodium Chloride IP 2.6 g Potassium Chloride IP 1.5g Trisodium Citrate 2.9g Dextrose (Anhydrous) 13.5g	01's	Bidder has requested for amendment in the name and detailed specification as	Amendment in the Generic Name is hereby authorized as:

				Orange Flavour		Oral Rehydration Salts IP (WHO Formula) Orange Flavour Sachet, <b>21.8g</b> instead of Oral Rehydration Salts IP (WHO Formula) Orange Flavour Sachet, <b>21g</b>	Oral Rehydration Salts IP (WHO Formula) Orange Flavour Sachet, 21.8g
47	Annexure - XII Clause 18 (M)	2467	Salmeterol 50mcg and Fluticasone 500mcg Rota caps	Each Hard Gelatin Capsule contains: Salmeterol 50mcg Fluticasone Propionate IP 500mcg	30's in PET bottle in monocation	Bidder has requested to amend and accept packaging specification as 30's in Plastic sealed air-tight container.	Amendment in the unit size is hereby authorized as: 30's in Air-tight PET bottle in monocation.
48	Annexure - XII Clause 18 (M)	2810	Fluoxetine IP 10mg Tablets	Each Film-Coated Tablet contains: Fluoxetine Hydrochloride IP equivalent to Fluoxetine 10mg	10's	Bidder has requested to accept the detailed specification as uncoated tablet form instead of film-coated tablet form.	<b><u>Tender condition prevails.</u></b>
49	Annexure - XII Clause 18 (M)	2825	Levetiracetam IP 500mg Prolonged Release Tablets	Each Film Coated Prolonged Release Tablet contains: Levetiracetam IP 500 mg	10's	Bidder has requested to accept the detailed specification as Film-coated tablet form instead of Film-coated prolonged-release tablet form.	<b><u>Tender condition prevails.</u></b>
50	Annexure - XII Clause 18 (M)	2838	Naltrexone IP 50mg Tablets	Each Uncoated Tablet contains: Naltrexone IP 50mg	10's	Bidder has requested to accept the packaging type as Blister pack instead of Alu-Alu pack	<b><u>Tender condition prevails.</u></b>
51	Annexure - XII Clause 18 (M)	2855	S-Amlodipine 2.5mg and Hydrochlorothiazide 12.5mg Tablets	Each Uncoated Tablet contains: S-Amlodipine Besylate IP equivalent to S-Amlodipine 2.5mg Hydrochlorothiazide IP 12.5mg	10's	Bidder has requested to amend and accept the unit size as 15's instead of 10's	<b><u>Tender condition prevails.</u></b>
52	Annexure - XII Clause 18 (M)	2864	Tianeptine 12.5mg Tablets	Each Sugar-Coated Tablet contains: Tianeptine Sodium 12.5mg	10's	Bidder has requested to accept the detailed specification as film-coated tablet form instead of sugar-coated tablet form. Also, bidder has requested to accept the packaging type as Alu-Alu pack instead of Strip pack	<b><u>Tender condition prevails.</u></b>
53	Annexure - XII Clause 18 (M)	2872	Ciclesonide 200mcg, Formoterol 6mcg and Tiotropium 9mcg Inhaler	Each Actuation Delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium 9mcg Formoterol Fumarate 6mcg (as Formoterol Fumarate Dihydrate IP) Ciclesonide IP 200mcg	200 MDI in 1 packet	Bidder has requested to amend the unit size as 180 MDI in 1 packet instead of 200 MDI in 1 packet.	<b><u>Tender condition prevails.</u></b>



- **Part-C**

**Clarification for the bidders if facing any issues in filling GST rates and HSN Code in the BOQ: -**

- Bidders facing issues while filling GST rates and HSN Code in BOQ may fill only Basic Rates in the Column 7 of the BOQ.
- Bidders shall fill applicable GST rates and HSN Code of quoted products in the below given format on duly signed Company Letterhead and shall submit the same with Technical Bid (Cover-A) of their bid.

**Format:**

S. No.	Drug Code	Generic Name of the Item	Unit Size	HSN Code	Applicable rate of GST%

**\*Note:** No Price-Bid (Cover-B) or basic rates shall be submitted with Technical Bid (Cover-A). Only HSN Code & GST rates shall be submitted on the company Letterhead duly signed by the authorized signatory. **Any violation may lead to rejection of the bid.**

**All other contents of tender document remain unaltered. Bidders are requested to quote their rates considering all the terms and condition of the tender document including Amendment No.1 dated 20/05/2025 and this Amendment No.2 dated 26/05/2025**

Sd/-

DGM (Procurement & Quality)  
For & on behalf of PMBI  
Ph: 011-49431800 (811)

Pharmaceuticals & Medical  
Devices Bureau of India